Urovant Sciences, Inc
5281 California Ave, Suite #100
Tel: +1 949 226 6029
About Urovant Sciences, Inc
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of urologic conditions. Our goal is to be the leading specialty company, recognized and trusted by patients and providers for our commitment to urology. At Urovant Sciences, we aim to advance urological patient care through execution of our core values:
Integrity and Compassion
Our commitment to improving patients’ lives begins with personal integrity and how we treat each other.
We deliver bold innovation through diversity of thought, openness to new ideas and adaptation to change.
Achievement Through Collaboration
We achieve excellence by uniquely optimizing our collective individual strengths and expertise.
Urovant Sciences is driving scientific innovation to improve the quality of life for patients living with urological conditions.
Our current area of research focus is Overactive Bladder (OAB). We are currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as third line treatments for OAB symptoms in patients who have failed oral pharmacologic therapy.
Every team member has the ability to make an impact to our success.
We are ambitious in our approach to improve outcomes for the patients and healthcare providers we serve. To challenge team members and grow careers, we reward innovation, teamwork, and a winning mindset that produces results.
Urovant Sciences is committed to developing medicines for urological conditions that allow people to live healthier and happier lives.
Our approach is rooted in social responsibility. We are committed to the health and well-being of the patients and healthcare providers we serve, to our employees, and to the communities in which we operate. Urovant Sciences supports policies that improve public health and access to life-impacting therapies regardless of race, ethnicity or ability to pay.
111 articles with Urovant Sciences, Inc
Dr. Frank Torti, former partner at NEA, appointed Vant Investment Chair
Three of Vivek Ramaswamy’s companies reported activity today including corporate changes, a licensed therapy and investment of $100 million.
One year after Vivek Ramaswamy launched Urovant Sciences to develop urological therapies, the company is now seeking $150 million from an initial public offering.
Urovant Sciences announced the appointments of Sef Kurstjens, M.D., Ph.D. and Pierre Legault to its board of directors.
Changes continue coming to Vivek Ramaswamy’s Roivant Sciences following a June shakeup that saw a 10 percent cut in employment and the restructuring of its business operations.
Urovant Sciences has been busy the past few weeks. In March the company initiated a Phase III trial for an overactive bladder treatment, strengthened its management team and established a U.S. headquarters in Irvine, California.
Urovant Sciences Strengthens Executive Management Team with Senior Hires and Establishes U.S. Headquarters in Irvine, California
Urovant Sciences announced that it has strengthened its management team through the appointment of five senior executives: Cornelia Haag-Molkenteller M.D., Ph.D., as Chief Medical Officer, Michael McFadden as Chief Commercial Officer, Bryan E. Smith as General Counsel, Christine Ocampo as Senior Vice President and Chief Accounting Officer, and Nori Ebersole as Senior Vice President and Chief Human Resources Officer.
Urovant Sciences Initiates Phase 3 Clinical Program for Vibegron in Patients with Overactive Bladder
Pivotal trial will enroll approximately 1,400 patients for 12-week treatment period.